Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A1 | P04798 | 2/20 | 1.00 |
| ▸ | CYP1B1 | Q16678 | 2/20 | 1.00 |
| ▸ | CYP19A1 | P11511 | 5/20 | 0.91 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.91 |
| ▸ | LMNA | P02545 | 4/20 | 0.91 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.91 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.91 |
| ▸ | MEN1 | O00255 | 2/20 | 0.91 |
| ▸ | GAA | P10253 | 2/20 | 0.91 |
| ▸ | MAPT | P10636 | 2/20 | 0.91 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.91 |
| ▸ | SHBG | P04278 | 2/20 | 0.91 |
| ▸ | TSHR | P16473 | 2/20 | 0.91 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.91 |
| ▸ | TP53 | P04637 | 1/20 | 0.91 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.91 |
| ▸ | THPO | P40225 | 1/20 | 0.91 |
| ▸ | GMNN | O75496 | 1/20 | 0.91 |
| ▸ | MTOR | P42345 | 1/20 | 0.91 |
| ▸ | BLM | P54132 | 1/20 | 0.91 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8489736 | 1.00 | CYP1A1 (1.00) | CYP1A1CYP1B1CYP19A1HSD17B10LMNA | |
| 2-Methoxyestradiol SCHEMBL119439 | 0.95 | CYP19A1 (1.00) | CYP1A1CYP1B1CYP19A1HSD17B10LMNA | |
| 2-Methoxyestradiol SCHEMBL8796 | 0.95 | CYP19A1 (1.00) | CYP1A1CYP1B1CYP19A1HSD17B10LMNA | |
| 2-Methoxyestradiol SCHEMBL26936622 | 0.95 | CYP19A1 (1.00) | CYP1A1CYP1B1CYP19A1HSD17B10LMNA | |
| 2-Methoxyestradiol SCHEMBL7052497 | 0.95 | CYP19A1 (1.00) | CYP1A1CYP1B1CYP19A1HSD17B10LMNA | |
| 2-Methoxyestradiol SCHEMBL23261536 | 0.95 | CYP19A1 (1.00) | CYP1A1CYP1B1CYP19A1HSD17B10LMNA | |
| 2-Methoxyestradiol SCHEMBL14252882 | 0.95 | CYP19A1 (1.00) | CYP1A1CYP1B1CYP19A1HSD17B10LMNA | |
| 2-Methoxyestradiol SCHEMBL13123068 | 0.95 | CYP19A1 (1.00) | CYP1A1CYP1B1CYP19A1HSD17B10LMNA | |
| 2-Methoxyestradiol SCHEMBL29357742 | 0.95 | CYP19A1 (1.00) | CYP1A1CYP1B1CYP19A1HSD17B10LMNA | |
| 2-Methoxyestradiol SCHEMBL2610023 | 0.95 | CYP19A1 (1.00) | CYP1A1CYP1B1CYP19A1HSD17B10LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2017189528-A1 | CORROSION INHIBITOR COMPOSITIONS AND METHODS OF USING SAME | Ecolab USA, Inc. (US) | 2017-11-02 | — | — | WO | claimed |
| US-20170306504-A1 | CORROSION INHIBITOR COMPOSITIONS AND METHODS OF USING SAME | CHAMPIONX LLC | 2017-10-26 | — | — | US | claimed |
| US-6172056-B1 | ADMINISTERING A ESTROGEN COMPOUND | JENAPHARM GMBH & CO. KG (DE) | 2001-01-09 | — | — | US | claimed |
| US-20250076302-A1 | DETECTING THE PRESENCE OF URINARY STONE DISEASE USING A PLURALITY OF URINARY METABOLITES | THE CLEVELAND CLINIC FOUNDATION | 2025-03-06 | — | — | US | disclosed |
| WO-2017189528-A1 | CORROSION INHIBITOR COMPOSITIONS AND METHODS OF USING SAME | Ecolab USA, Inc. (US) | 2017-11-02 | — | — | WO | disclosed |
| US-20170306504-A1 | CORROSION INHIBITOR COMPOSITIONS AND METHODS OF USING SAME | CHAMPIONX LLC | 2017-10-26 | — | — | US | disclosed |
| US-20080293683-A1 | Hormone Replacement Therapy | UNIVERSITY OF KANSAS MEDICAL CENTER (US) | 2008-11-27 | — | — | US | disclosed |
| US-20070275935-A1 | Estratriene Derivatives | CRYPTOPHARMA PTY LTD (AU) | 2007-11-29 | — | — | US | disclosed |
| EP-1625143-A1 | ESTRATRIENE DERIVATIVES | Cryptopharma Pty Ltd (AU) | 2006-02-15 | — | — | EP | disclosed |
| WO-2004101595-A1 | ESTRATRIENE DERIVATIVES | CRYPTOPHARMA PTY LTD (AU) | 2004-11-25 | — | — | WO | disclosed |
| US-6274118-B1 | INJECTING PATIENT HAVING ENDOCRINE CANCER IN NON-PROSTATIC TISSUE WITH BIOLOGICAL BINDING UNITS WHICH BIND TO PROSTATE SPECIFIC ANTIGEN PRODUCED BY NON-PROSTATIC TISSUE | NORDION INTERNATIONAL INC. (CA) | 2001-08-14 | — | — | US | disclosed |
| US-6172056-B1 | ADMINISTERING A ESTROGEN COMPOUND | JENAPHARM GMBH & CO. KG (DE) | 2001-01-09 | — | — | US | disclosed |
| US-6172056-B1 | ADMINISTERING A ESTROGEN COMPOUND | JENAPHARM GMBH & CO. KG (DE) | 2001-01-09 | — | — | US | disclosed |
| WO-1995002424-A1 | LOCALIZATION AND THERAPY OF NON-PROSTATIC ENDOCRINE CANCER WITH AGENTS DIRECTED AGAINST PROSTATE SPECIFIC ANTIGEN | NORDION INTERNATIONAL INC. (CA) | 1995-01-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080293683-A1 | Hormone Replacement Therapy | ESR2, SHBG, ESRRG | CYP1A1 818/4885CYP1B1 1095/4885CYP19A1 13/4885 |
| US-20070275935-A1 | Estratriene Derivatives | ESR2, ESRRB, NR3C2 | CYP1A1 234/4885CYP1B1 210/4885CYP19A1 20/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.